Curapel

Curapel is a UK-based company focused on creating innovative dermatological solutions to treat chronic skin conditions, utilizing naturally-derived ingredients backed by clinical validation. Curapel specializes in developing treatments for chronic skin conditions. Founded by Neil Frsb, the company has raised a total of GBP 0. 35 mn in funding since its establishment in 2014, with the most recent funding round occurring on May 22, 2016.

The company has been involved in one deal with investors including Development Bank of Wales and Lancaster Capital. Curapel’s headquarters is located in the UK. Curapel offers a range of dermatological products aimed at chronic skin conditions, including Pellamex, Pelladerm, and Pellatone. These products are designed to nourish the skin's protective barrier, alleviate psoriasis, and enhance skin tone, respectively.

All formulations utilize naturally occurring ingredients and have been clinically validated for safety and effectiveness, catering primarily to consumers in Europe and North America. Since its inception in 2014, Curapel has raised over GBP 2. 4 mn through grants and equity investments. The company generates revenue primarily through direct-to-consumer sales and partnerships with healthcare providers, offering innovative products to individuals with chronic skin conditions and supporting ongoing research and development.

Curapel plans to leverage the GBP 0. 35 mn raised in May 2016 to support the development of new products and expand into new markets. The company is focused on launching additional skincare products tailored for specific chronic conditions, while also targeting growth in markets across Europe and North America by 2025.